Nestlé’s response to concerns about oral rehydration solution
BMJ 2010; 341 doi: https://doi.org/10.1136/bmj.c6167 (Published 02 November 2010) Cite this as: BMJ 2010;341:c6167- Ferdinand Haschke, director1
- 1Nestlé Nutrition Institute, Avenue Reller 14, 1800 Vevey, Switzerland
- ferdinand.haschke{at}nestle.com
A Nestlé maltodextrin based oral rehydration solution (ORS) has been sold under various trade names in several European countries. In all of these countries and for two decades this product has proved safe and efficacious as an ORS for treatment of diarrhoea and acute gastroenteritis. The product was introduced under the brand name Resorb Junior Plus in Sweden in 2009. In April 2010 Nestlé decided to withdraw the product from the Swedish market because of reports of a few unexpected cases of worsening dehydration and hypernatremia during treatment of young children.1 (See also letter from Lidefelt and colleagues.2)
After a meeting between the Nestlé Nutrition Institute and Karolinska Hospital, a collaboration was established to find the cause of the unexpected adverse reactions. A review of …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.